[Male breast cancer].
Shin
E
E
Department of Surgery, Osaka National Hospital.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein; D018567:Breast Neoplasms, Male / Q000209:etiology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D004965:Estrogen Antagonists / Q000627:therapeutic use; D004967:Estrogens / Q000009:adverse effects; D005262:Feminization / Q000150:complications; D018095:Germ-Line Mutation; D006801:Humans; D007713:Klinefelter Syndrome / Q000150:complications; D008297:Male; D015412:Mastectomy, Segmental; D009363:Neoplasm Proteins / Q000235:genetics; D011379:Prognosis; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use; D014157:Transcription Factors / Q000235:genetics
D018931:Antineoplastic Agents, Hormonal; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D004965:Estrogen Antagonists; D004967:Estrogens; D009363:Neoplasm Proteins; D014157:Transcription Factors; D013629:Tamoxifen